Olink Proteomics Analysis Reveals Heterogeneous Responses to <scp>FcRn</scp> Blockade in Anti‐ <scp>AChR</scp> Antibody‐Positive Myasthenia Gravis: <scp>FGF</scp> ‐19 as a Novel Biomarker
EFG treatment can alleviate the clinical symptoms and decrease IgG levels in patients with MG. The downregulated expression following EFG treatment, along with the findings of in vitro experiments, indicates that FGF-19 may not only act as a biomarker for the efficacy of EFG, but also play a role in promoting the differentiation of B cells into plasma cells, thereby offering a novel target for therapeutic interventions.
Authors
- Xinyan Guo
- Mingjin Yang (ORCID: https://orcid.org/0009-0006-2208-4876)
- Mingming Xu (ORCID: https://orcid.org/0009-0007-4167-3729)
- Tianyu Ma (ORCID: https://orcid.org/0000-0002-2326-5760)
- Zhouao Zhang (ORCID: https://orcid.org/0009-0000-6253-6167)
- Linlin Fu
- Xiaoyu Huang (ORCID: https://orcid.org/0000-0002-0993-6994)
- Tiancheng Luo (ORCID: https://orcid.org/0000-0002-8309-4158)
- Deliang Peng
- Yong Zhang
Institutions
- Xuzhou Medical College (CN)
- Third People's Hospital of Hangzhou (CN)
- Xuzhou Central Hospital (CN)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1002/acn3.70261
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Commission of Health
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Xuzhou Medical University